Baldwin Brothers LLC MA lowered its position in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 36.3% during the first quarter, HoldingsChannel reports. The firm owned 2,210 shares of the medical research company’s stock after selling 1,262 shares during the period. Baldwin Brothers LLC MA’s holdings in Amgen were worth $534,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $1,138,930,000. BlackRock Inc. raised its stake in shares of Amgen by 2.1% during the fourth quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock valued at $11,258,926,000 after purchasing an additional 1,032,929 shares during the period. Renaissance Technologies LLC raised its stake in shares of Amgen by 625.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,101,853 shares of the medical research company’s stock valued at $247,884,000 after purchasing an additional 950,008 shares during the period. First Trust Advisors LP raised its stake in shares of Amgen by 125.5% during the fourth quarter. First Trust Advisors LP now owns 1,613,704 shares of the medical research company’s stock valued at $363,035,000 after purchasing an additional 898,059 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Amgen by 6.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,725,125 shares of the medical research company’s stock valued at $1,962,892,000 after purchasing an additional 561,955 shares during the period. Institutional investors own 79.01% of the company’s stock.
A number of analysts recently issued reports on AMGN shares. Morgan Stanley dropped their price target on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. TheStreet lowered shares of Amgen from a “b+” rating to a “c+” rating in a research note on Wednesday, April 27th. BMO Capital Markets dropped their price target on shares of Amgen from $263.00 to $243.00 in a research note on Thursday, April 28th. SVB Leerink started coverage on shares of Amgen in a research note on Monday, May 23rd. They issued a “market perform” rating and a $256.00 price target for the company. Finally, Oppenheimer lifted their price target on shares of Amgen from $285.00 to $290.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $242.57.
Shares of AMGN opened at $240.14 on Thursday. Amgen Inc. has a 1 year low of $198.64 and a 1 year high of $258.45. The company has a market cap of $128.28 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44. The firm has a fifty day moving average of $244.62 and a 200-day moving average of $234.69.
Amgen (NASDAQ:AMGN – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The company had revenue of $6.24 billion during the quarter, compared to the consensus estimate of $6.09 billion. During the same quarter in the previous year, the company posted $3.70 earnings per share. Analysts predict that Amgen Inc. will post 17.44 EPS for the current year.
Amgen Company Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.